Why aren’t people using Paxlovid?

Paxlovid (nirmatrelvir-ritonavir) is effective at preventing hospitalization and death from COVID-19, but few people use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to find out why. Their survey revealed patients had a lack of awareness of the treatment as well as misinformation about the treatment (among those who were aware…

Links

Tyler Cowen on the price of Ozempic. Problems with the OMB’s social welfare function. Link between alcohol and cancer. Disparities in the rural-urban life expectancy. Why will Part D plans “…move drugs that are selected for [MFP] negotiation into a higher cost-sharing tier”?

Why aren’t alternative payment models working?

Out of more than 50 alternative payment models (APM) that CMS has implemented only six have shown statistically significant cost savings and only four of these met the requirements to be expanded in duration and scope. That is not my opinion, CMS itself states this. We all want higher quality at lower cost; so the…

Healthcare spending for individuals with FSAs and HSAs

In the U.S., health insurance premiums are tax deductible–if paid through out of pocket expenses–but out-of-pocket expenses are not. However, there are exceptions to this rule. These include two often-used tax-favored accounts: Flexible savings accounts (FSA). These accounts allow employees to set aside a portion of their pretax income to cover qualified medical expenses; however,…

FTC to sue PBMs over insulin pricing and rebates

From the FTC’s press release out today: Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’…

Links

Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost of care under Medicare vs. Medicaid. The Less-Efficient Market Hypothesis. Semaglutide and COVID-19. Statistical Modeling, Causal Inference, and Social Science turns 20.

Some hopeful trends on opioid overdoses (finally)

While opioid overdoses have been rising for decades, trends in most recent times provide us a glimmer of hope. NPR reports: For the first time in decades, public health data shows a sudden and hopeful drop in drug overdose deaths across the U.S.“This is exciting,” said Dr. Nora Volkow, head of the National Institute On…